Unity Biotechnology, Inc. (UNBX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Unity Biotechnology, Inc. (UNBX) trades at $0.0561. Unity Biotechnology, Inc. is a biotechnology company focused on developing therapies for aging-related diseases. Their programs target ophthalmologic and neurologic disorders. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for UNBX: UNBX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UNBX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
UNBX: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Unity Biotechnology, Inc. (UNBX) Healthcare & Pipeline Overview
Unity Biotechnology, Inc. is a biotechnology company focused on developing senolytic medicines to treat age-related diseases, particularly those affecting the eye and brain. With a small team, they are navigating the high-risk, high-reward landscape of pharmaceutical research and development within the competitive biotechnology sector.
What Is the Investment Thesis for UNBX?
Unity Biotechnology operates in the high-risk, high-reward biotechnology sector, focusing on senolytic therapies for age-related diseases. The company's value hinges on the successful development and clinical validation of its drug candidates, particularly those targeting ophthalmologic and neurologic disorders. Key value drivers include positive clinical trial results, strategic partnerships, and regulatory approvals. The investment thesis is predicated on the potential of senolytics to address unmet medical needs in aging populations, but is tempered by the inherent risks of drug development, including clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies. Given the company's small market capitalization and OTC listing, liquidity and volatility are also important considerations for investors.
Based on FMP financials and quantitative analysis
UNBX Key Highlights
Unity Biotechnology focuses on developing senolytic medicines to treat age-related diseases.
- The company's primary focus is on ophthalmologic and neurologic disorders.
- Unity Biotechnology operates in the high-risk, high-reward biotechnology sector.
- The company's market capitalization is $0.00B as of 2026-03-16.
- Craig R. Jalbert manages a team of 16 employees.
Who Are UNBX's Competitors?
UNBX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CAIHF Chia Tai Enterprises International Limited | $1.07 | +0.00% | $258M | 53 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UNBX's Key Strengths?
Proprietary senolytic technology
- Focus on a growing market (aging-related diseases)
- Potential for disease-modifying therapies
- Experienced management team
What Are UNBX's Weaknesses?
Limited financial resources
- High dependence on clinical trial success
- Small team size
- OTC listing may limit investor access
What Could Drive UNBX Stock Higher?
Clinical trial data releases for lead senolytic candidates.
- Potential strategic partnerships with larger pharmaceutical companies.
- Regulatory submissions for key therapies.
- Advancements in senolytic technology and research.
- Increased awareness and acceptance of senolytics as a therapeutic approach.
What Are the Key Risks for UNBX?
Clinical trial failures or negative data readouts.
- Regulatory setbacks or delays in approval process.
- Competition from established pharmaceutical companies with more resources.
- Limited financial resources to fund research and development.
- OTC listing may limit investor access and liquidity.
What Are the Growth Opportunities for UNBX?
- Expansion of Pipeline: Unity Biotechnology has the opportunity to expand its pipeline of senolytic candidates to target a broader range of age-related diseases. This includes exploring new therapeutic areas beyond ophthalmology and neurology, such as musculoskeletal disorders or cardiovascular diseases. Successful expansion would require significant investment in research and development, but could substantially increase the company's market potential and long-term growth prospects. The timeline for this growth opportunity is dependent on preclinical and clinical trial progress, with potential for new candidates entering clinical trials within the next 2-3 years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide Unity Biotechnology with access to additional funding, expertise, and resources. These partnerships could accelerate the development and commercialization of its senolytic therapies, as well as expand its market reach. Potential partners could include companies with established expertise in ophthalmology or neurology, or those with a strong interest in aging-related diseases. The timeline for securing strategic partnerships is uncertain, but could occur within the next 1-2 years.
- Positive Clinical Trial Results: Achieving positive results in clinical trials for its lead senolytic candidates is critical for Unity Biotechnology's growth. Successful clinical trials would validate the efficacy and safety of its therapies, increasing their attractiveness to potential partners and investors. Positive data could also lead to accelerated regulatory approval and commercialization. The timeline for clinical trial results is dependent on the progress of ongoing studies, with potential for data readouts within the next 1-2 years.
- Regulatory Approval: Obtaining regulatory approval from agencies such as the FDA is a major milestone for any biotechnology company. Successful approval of Unity Biotechnology's senolytic therapies would allow them to be marketed and sold to patients, generating revenue and establishing the company as a leader in the field of aging-related diseases. The timeline for regulatory approval is dependent on the completion of clinical trials and the submission of a comprehensive regulatory package, with potential for approval within the next 3-5 years.
- Commercialization: Successful commercialization of its senolytic therapies is the ultimate goal for Unity Biotechnology. This includes establishing a sales and marketing infrastructure, securing reimbursement from payers, and effectively reaching patients in need. Commercialization would require significant investment and expertise, but could generate substantial revenue and establish the company as a sustainable business. The timeline for commercialization is dependent on regulatory approval and the development of a robust commercial strategy, with potential for product launches within the next 3-5 years.
What Are UNBX's Competitive Advantages?
- Patented senolytic therapies
- Proprietary research and development platform
- First-mover advantage in the senolytics field
- Expertise in aging-related diseases
What Does UNBX Do?
Unity Biotechnology, Inc., based in San Francisco, is a biotechnology company focused on developing therapies to slow, halt, or reverse diseases associated with aging. The company's approach centers around senolytics, a class of drugs designed to selectively eliminate senescent cells, which are cells that have stopped dividing and can contribute to inflammation and tissue dysfunction. Unity Biotechnology's research and development efforts are primarily directed towards addressing age-related diseases in ophthalmology and neurology. Their pipeline includes senolytic candidates targeting conditions such as glaucoma and other age-related macular degenerations. Founded with the vision of extending healthy human lifespan, Unity Biotechnology aims to translate its scientific discoveries into disease-modifying treatments. The company operates within the highly competitive biotechnology industry, characterized by significant research and development investments, regulatory hurdles, and the potential for substantial returns upon successful drug development and commercialization. As of 2026, Unity Biotechnology continues to advance its preclinical and clinical programs, seeking to demonstrate the efficacy and safety of its senolytic therapies.
What Products and Services Does UNBX Offer?
- Develop senolytic medicines
- Target age-related diseases
- Focus on ophthalmologic disorders
- Focus on neurologic disorders
- Conduct preclinical research
- Conduct clinical trials
- Seek regulatory approval for therapies
How Does UNBX Make Money?
- Develop and patent novel senolytic therapies.
- Conduct research and clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval from agencies like the FDA.
- Potentially partner with larger pharmaceutical companies for commercialization.
- Generate revenue through sales of approved therapies or licensing agreements.
What Industry Does UNBX Operate In?
Unity Biotechnology operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory scrutiny, and significant financial investment. The industry is driven by the increasing demand for innovative therapies to address unmet medical needs, particularly in areas such as aging-related diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in specific therapeutic areas. Market trends include the growing adoption of precision medicine, the increasing importance of biomarkers, and the rising costs of drug development. Unity Biotechnology's focus on senolytics positions it within a niche segment of the aging-related disease market, offering potential for targeted therapies.
Who Are UNBX's Key Customers?
- Patients with age-related ophthalmologic disorders
- Patients with age-related neurologic disorders
- Potential pharmaceutical partners
- Healthcare providers
Company Profile
Unity Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Craig R. Jalbert. UNBX has traded publicly since 2018.
Key Financial Metrics
Return on assets is -69.0%, showing how much profit it generates from its asset base. A current ratio of 2.62 indicates the company holds enough short-term assets to cover its near-term obligations.
UNBX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying signals confidence, potentially a strong long-term play.
- The community is buzzing about upcoming data releases, creating a 'wait and see' optimism.
- Market perception suggests potential for a breakthrough in age-related disease treatments.
- Bullish sentiment highlights the company's innovative approach to cellular senescence.
Bear Case
- Insider activity is mixed; some recent selling could indicate short-term concerns.
- Community sentiment shows skepticism about the efficacy of their current pipeline.
- Market perception is cautious given past trial failures in the biotech sector.
- Bearish views focus on the high cash burn rate and uncertain path to profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
UNBX Latest News
No recent news available for UNBX.
UNBX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UNBX.
Price Targets
Wall Street price target analysis for UNBX.
UNBX MoonshotScore
What does this score mean?
The MoonshotScore rates UNBX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Craig R. Jalbert
CEO
Craig R. Jalbert serves as the CEO of Unity Biotechnology, leading a team of 16 employees. Information about his detailed career history and educational background is not available in the provided data. As CEO, he is responsible for the overall strategic direction and operational execution of the company's research and development programs, as well as its financial performance and investor relations. His leadership is critical to navigating the challenges and opportunities of the biotechnology industry, particularly in the field of aging-related diseases.
Track Record: Due to the limited information available, it is not possible to assess Craig R. Jalbert's specific achievements, strategic decisions, or company milestones under his leadership at Unity Biotechnology. His track record would be reflected in the company's progress in advancing its clinical pipeline, securing partnerships, and achieving regulatory milestones. Further information would be needed to evaluate his performance.
UNBX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Unity Biotechnology may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, and there may be less information available to investors. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ due to the potential for limited liquidity, increased volatility, and less stringent regulatory oversight.
- OTC Tier: OTC Other
- Limited liquidity due to OTC listing
- Less stringent regulatory oversight compared to major exchanges
- Potential for limited financial disclosure
- Increased price volatility
- Higher risk of fraud or manipulation
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has a functioning website and contact information.
- Management team has relevant experience in the biotechnology industry.
- Company has patents or pending patent applications for its senolytic therapies.
- Company is actively engaged in research and development activities.
- Company has a clear business plan and strategy for growth.
Unity Biotechnology, Inc. Healthcare Stock: Key Questions Answered
What does Unity Biotechnology, Inc. do?
Unity Biotechnology, Inc. is a biotechnology company focused on developing senolytic medicines, which are designed to selectively eliminate senescent cells that contribute to age-related diseases. Their primary focus is on developing therapies for ophthalmologic and neurologic disorders, with the goal of slowing, halting, or reversing the progression of these diseases.
What are the main risks for UNBX?
The main risks for Unity Biotechnology, Inc. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory setbacks. As a biotechnology company with limited financial resources, UNBX is also vulnerable to funding challenges and competition from larger pharmaceutical companies. The company's OTC listing adds additional risks related to liquidity, volatility, and regulatory oversight. Investors should carefully consider these risks before investing in UNBX.
What are the key factors to evaluate for UNBX?
Evaluate UNBX on fundamentals, analyst consensus, and risk factors. Unity Biotechnology operates in the high-risk, high-reward biotechnology sector, focusing on senolytic therapies for age-related diseases. Not financial advice.
How frequently does UNBX data refresh on this page?
UNBX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven UNBX's recent stock price performance?
Unity Biotechnology, Inc. (UNBX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary senolytic technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UNBX overvalued or undervalued right now?
Unity Biotechnology, Inc. (UNBX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research UNBX before investing?
Before investing in Unity Biotechnology, Inc. (UNBX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding UNBX to a portfolio?
Key strength of Unity Biotechnology, Inc. (UNBX): Proprietary senolytic technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending and may provide additional insights.
- OTC stocks carry higher risk than exchange-listed stocks.